Table 2. Published studies evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) as prophylactic treatment in absence of peritoneal metastases.
| Author, year | Number of patients | Drug | Morbidity | Survival |
|---|---|---|---|---|
| Koga 1998, (49) | 26 (surgery + HIPEC) vs. 21 (surgery alone) | MMC | Anastomotic leak: 3.1% vs. 7.1% | 30-month OS: 83% vs. 67% |
| Ikeguchi 1995, (50) | 78 (surgery + HIPEC) vs. 96 (surgery alone) | MMC | 1.2% vs. 2.1% | 5-year OS: 51% vs. 46% |
| Fujimoto 1999, (51) | 71 (surgery + HIPEC) vs. 70 (surgery alone) | MMC | 2/71 vs. 2/70 | 4-year OS: 76% vs. 58% |
| Yonemura 2001, (46) | 48 (surgery + HIPEC) vs. 44 (surgery + NIPEC) vs. 47 (surgery alone) | MMC + Cisplatin | 19% vs. 14% vs. 19% (mortality: 4% vs. 0% vs. 4%) | 5-year OS: 61% vs. 44% vs. 42% |
| Zhu 2006, (52) | 41 (surgery + HIPEC) vs. 53 (surgery alone) | MMC + Cisplatin | 23% vs. 12% | 4-year OS: 70% vs. 52% |
| Coccolini 2014, (22) | 116 (surgery + HIPEC) vs. 88 (surgery alone) | MMC, Cisplatin | Morbidity rate better in surgery group (OR =1.82) | 2-year OS: better in HIPEC (OR =0.24) |
| Desiderio 2017, (23) | 731 (surgery + HIPEC) vs. 1,079 (surgery alone) | MMC, cisplatin, etoposide | Higher risk in HIPEC group (RR =2.17) | 5-year OS better in HIPEC (RR =0.82) |
MMC, mitomycin C; OS, overall survival; NIPEC, normothermic intraperitoneal chemotherapy.